ICD-10-PCS Codes

• 1 XW04306 (INTRODUCTION OF BREXANOLONE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 2 XW04308 (INTRODUCTION OF SPESOLIMAB MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 3 XW04321 (INTRODUCTION OF CEFTAZIDIME-AVIBACTAM ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 1)

• 4 XW04326 (INTRODUCTION OF NERINITIDE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 5 XW04331 (INTRODUCTION OF IDARUCIZUMAB, DABIGATRAN REVERSAL AGENT INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 1)

• 6 XW04336 (INTRODUCTION OF DURVALUMAB ANTINEOPLASTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 7 XW04341 (INTRODUCTION OF ISAVUCONAZOLE ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 1)

• 8 XW04351 (INTRODUCTION OF BLINATUMOMAB ANTINEOPLASTIC IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 1)

• 9 XW04357 (INTRODUCTION OF NARSOPLIMAB MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 10 XW04358 (INTRODUCTION OF MOSUNETUZUMAB ANTINEOPLASTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 11 XW04366 (INTRODUCTION OF LEFAMULIN ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 12 XW04367 (INTRODUCTION OF TERLIPRESSIN INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 13 XW04368 (INTRODUCTION OF AFAMITRESGENE AUTOLEUCEL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 14 XW04372 (INTRODUCTION OF INACTIVATED COAGULATION FACTOR XA INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 2)

• 15 XW04377 (INTRODUCTION OF TRILACICLIB INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 16 XW04378 (INTRODUCTION OF TABELECLEUCEL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 17 XW04387 (INTRODUCTION OF LURBINECTEDIN INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 18 XW04388 (INTRODUCTION OF TREOSULFAN INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 19 XW04392 (INTRODUCTION OF DEFIBROTIDE SODIUM ANTICOAGULANT INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 2)

• 20 XW04396 (INTRODUCTION OF CEFTOLOZANE/TAZOBACTAM ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 21 XW04398 (INTRODUCTION OF INEBILIZUMAB-CDON INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 22 XW043A3 (INTRODUCTION OF BEZLOTOXUMAB MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 3)

• 23 XW043A6 (INTRODUCTION OF CEFIDEROCOL ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 24 XW043A7 (INTRODUCTION OF CILTACABTAGENE AUTOLEUCEL INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 25 XW043B3 (INTRODUCTION OF CYTARABINE AND DAUNORUBICIN LIPOSOME ANTINEOPLASTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 3)

• 26 XW043B6 (INTRODUCTION OF OMADACYCLINE ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 27 XW043B7 (INTRODUCTION OF AMIVANTAMAB MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 28 XW043C3 (INTRODUCTION OF ENGINEERED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 3)

• 29 XW043C6 (INTRODUCTION OF ECULIZUMAB INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 30 XW043C7 (INTRODUCTION OF AUTOLOGOUS ENGINEERED CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 31 XW043D6 (INTRODUCTION OF ATEZOLIZUMAB ANTINEOPLASTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 32 XW043E5 (INTRODUCTION OF REMDESIVIR ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 33 XW043E6 (INTRODUCTION OF ETESEVIMAB MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 34 XW043F3 (INTRODUCTION OF OTHER NEW TECHNOLOGY THERAPEUTIC SUBSTANCE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 3)

• 35 XW043F5 (INTRODUCTION OF OTHER NEW TECHNOLOGY THERAPEUTIC SUBSTANCE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 36 XW043F6 (INTRODUCTION OF BAMLANIVIMAB MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 37 XW043G5 (INTRODUCTION OF SARILUMAB INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 38 XW043G6 (INTRODUCTION OF REGN-COV2 MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 39 XW043G7 (INTRODUCTION OF ALLOGENEIC ENGINEERED CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 40 XW043H5 (INTRODUCTION OF TOCILIZUMAB INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 41 XW043H6 (INTRODUCTION OF OTHER NEW TECHNOLOGY MONOCLONAL ANTIBODY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 42 XW043H7 (INTRODUCTION OF AXICABTAGENE CILOLEUCEL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 43 XW043J7 (INTRODUCTION OF TISAGENLECLEUCEL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 44 XW043K5 (INTRODUCTION OF FOSFOMYCIN ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 45 XW043K7 (INTRODUCTION OF IDECABTAGENE VICLEUCEL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 46 XW043K9 (INTRODUCTION OF SULBACTAM-DURLOBACTAM INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 47 XW043L6 (INTRODUCTION OF CD24FC IMMUNOMODULATOR INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 48 XW043L7 (INTRODUCTION OF LIFILEUCEL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 49 XW043M7 (INTRODUCTION OF BREXUCABTAGENE AUTOLEUCEL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 50 XW043N5 (INTRODUCTION OF MEROPENEM-VABORBACTAM ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 51 XW043N7 (INTRODUCTION OF LISOCABTAGENE MARALEUCEL IMMUNOTHERAPY INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 52 XW043P9 (INTRODUCTION OF GLOFITAMAB ANTINEOPLASTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 53 XW043Q5 (INTRODUCTION OF TAGRAXOFUSP-ERZS ANTINEOPLASTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 54 XW043Q9 (INTRODUCTION OF POSOLEUCEL INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 55 XW043R9 (INTRODUCTION OF REZAFUNGIN INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 56 XW043S5 (INTRODUCTION OF IOBENGUANE I-131 ANTINEOPLASTIC INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 57 XW043U5 (INTRODUCTION OF IMIPENEM-CILASTATIN-RELEBACTAM ANTI-INFECTIVE INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 58 XW043W5 (INTRODUCTION OF CAPLACIZUMAB INTO CENTRAL VEIN, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)